Sun Pharma NJ Plant Passes FDA Review After Warning

Law360, New York (September 19, 2011, 7:41 PM EDT) -- The U.S. Food and Drug Administration last week approved Sun Pharmaceutical Industries Ltd.’s corrective actions at a Cranbury, N.J., manufacturing plant cited last year for quality control violations that included imploding pill bottles and drug defects.

In a Sept. 13 letter, the FDA told Sun that after the agency's most recent inspection of the plant, the drugmaker appeared to have addressed a litany of current good manufacturing practices violations in a warning issued in August 2010.

Early last year, the FDA slammed Sun for poor handling...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.